PCD12: SPIRONOLACTONE IN HEART FAILURE: LIFE AND COST SAVING TREATMENT IN POLAND  by Kuzniar, J et al.
Abstracts 71
astatin and simvastatin, priced the same as the next-high-
est dose of each agent, suggests that segmentation in the
statin marketplace may be decreasing, with potential im-
plications for economic efficiency. OBJECTIVE: To reas-
sess economic segmentation in the statin marketplace in
light of the introduction of higher doses of cerivastatin
and simvastatin. METHODS: We used a Markov model
of the medical and economic consequences of lipid regu-
lating therapy to assess the cost-effectiveness of all statin
doses approved for marketing in the US as of January
2000. Cost-effectiveness was assessed for “high risk” men
(age 65 years, history of CHD, diabetic) and “low risk”
women (age 55 years, free of CHD with no other risk
factors). RESULTS: Cerivastatin 0.4 mg has the lowest
cost per life year gained relative to no therapy ($7200 for
high-risk men and $248,000 for low-risk women), while
lovastatin 80 mg has the highest ($35,000 and $1,067,000,
respectively). However, simvastatin 80 mg does not sup-
plant atorvastatin as the efficient choice for persons re-
quiring aggressive CHD risk reduction. Frontier analysis
suggests that cerivastatin is the most efficient choice for
persons requiring reductions in CHD risk of 18%
(high-risk men) and 31% (low-risk women), while
atorvastatin remains the most efficient choice for patients
requiring larger reductions. CONCLUSION: The recent
introduction of cerivastatin 0.4 mg has made it the effi-
cient choice for a wider range of patients based on their
target risk reduction and has blurred the previous distinc-
tion between statin market segments.
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Heart failure (HF) is a major source of morbidity, mor-
tality and medical costs. An early HF diagnosis and treat-
ment (I–II NYHA-class) may be one of the ways to opti-
mize outcomes. It needs such methods as Doppler and
stress echocardiography to reveal systolic and diastolic
ventricular dysfunction and ACE-inhibitors to improve
structure and functional disorders. High costs of these di-
agnostic procedures and medicines limit their widespread
use. OBJECTIVES: The purpose of this study was to
evaluate cost-effectiveness of diagnosing HF I–II vs III–IV
NYHA class. METHODS: A model considering cohort
specification (NYHA class, diagnostic procedures) was
developed to compare medical outcomes (complications,
hospitalization, mortality etc). The model was based on
expert’s conclusions and medical literature. RESULTS:
The medical costs of diagnosing and treating I–II class
HF (including direct costs to diagnostic, treatment, hospi-
talization and readmission) were less than for HF III–IV
class (514 vs 1165 roubles). But because prevalence of
HF I–II is higher than HF III–IV, the direct costs of diag-
nosing and treating HF I–II prevails in population
(432.264 vs 186.400 roubles per 100.000 patients).
CONCLUSIONS: From a community point of view early
diagnosis and treatment for HF is not cost-effective in the
1st year. Still effective treatment in early stages of HF
must change the proportion of HF NYHA classes in the
community, and in some years will lead to decrease in
overall costs for HF treatment. Further economic analysis
must be performed to assess long-terms outcomes.
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The RALES study indicates that addition of spironolac-
tone (S) to standard treatment (diuretics, ACE inhibitors,
glycosides) of patients with congestive heart failure
(CHF) (NYHA III–IV, EF  25%) results in statistically
and clinically significant prolongation of survival. OB-
JECTIVE: Cost-effectiveness analysis of S versus placebo
in conjunction with standard treatment, in the manage-
ment of CHF. METHODS: RALES results were used to
estimate the increase in survival and the reduction in the
number of hospitalizations arising from the use of S in
management of CHF. Life-years saved were estimated
from RALES data using survival curves analysis. Direct
medical costs were estimated on the basis of Polish
sources. The perspective of the health care payers and a
time frame of two years was taken. A decision model was
used. Sensitivity analysis (Monte Carlo) was performed.
RESULTS: S increased mean survival (1.41 months per
patient/2 years) and was cost saving, reducing direct
medical costs for CHF patients over 2 years by 348 zl
($84.9). One-way sensitivity analysis indicated that ther-
apy with spironolactone remained cost saving even when
drug cost was increased four times and the risk of hospi-
talization in the S group was increased by 20%. When
three variables (frequency, hospitalization cost, life-years
saved) were changed simultaneously, in 73.8% simula-
tions ICER value was negative, and 90% were in range
(21097/8524 zl). CONCLUSION: Addition of S to
standard management of CHF in Poland should improve
survival and may provide a net reduction in treatment
costs. Economic significance is highlighted by 100,000/
year hospitalization due to CHF in Poland.
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The results of the SOLVID trial demonstrating the sur-
vival benefit of enalapril (E) treatment of congestive heart
